RxDoctor Payments Data

Sudha Nahar, MD

Gastroenterology · Somerset, NJNPI 1164463071

Payments from drug & device makers

$1,057in general payments, 2019–2025

Across 34 payments — averaging $31.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$330
  • AbbVie$297
  • Phathom Pharmaceuticals, Inc.$123
  • Pharmacosmos Therapeutics Inc.$101
  • Novo Nordisk$69
  • Abbott$68
  • plus $70 from 2 others

What the payments were for

  • Speaking & faculty fees$202%
  • Grants$202%
  • Food & beverage$99995%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,057 in reported general payments places this provider in the 30th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$79,656
Medicare patients
203
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide18$11,167
Dexlansoprazole DrDexlansoprazole28$7,862
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates119$7,390
Sucralfate36$6,162
Esomeprazole Magnesium163$4,229
Balsalazide Disodium16$2,406
Pantoprazole Sodium145$1,838
Famotidine104$1,716
CholestyramineCholestyramine (With Sugar)14$1,270
Omeprazole103$921
Mesalamine ErMesalamine13$547
Ursodiol15$546
Lactulose24$494
Ondansetron OdtOndansetron11$226
Dicyclomine Hcl18$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$297$11,16718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Somerset

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →